Fyrwald J Erik has reported a transaction involving 7.9951 shares of Eli Lilly & Co, valued at approximately $9,918.38. This transaction is significant as it demonstrates Erik's ongoing engagement with the company and may influence investor confidence.
Eli Lilly & Co, known for its pharmaceutical preparations, operates in a highly competitive industry. The company, with a central index key of 0000059478, is based in Indianapolis, Indiana, and is a key player in the life sciences sector.
According to the recent SEC filing (accession number 0000059478-26-000097), the transaction took place on October 19, 2026. The filing states that Erik acquired 7.9951 shares at a price of $1240.34 per share. Following this transaction, Erik now owns a total of 75,544.1259 shares of Eli Lilly & Co.
The filing also notes that the shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. This plan allows for the settlement of shares of common stock following Erik's separation from service.
This acquisition may impact various stakeholders, including investors and analysts who monitor Eli Lilly's performance and governance. The pharmaceutical industry remains competitive, with other major companies also vying for market share.
Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this transaction.